Economist argues maximizing shareholder value hurts drug innovation

By Daniel Levine

“The pharmaceutical industry has long argued that high drug prices are necessary to incentivize investment in and fund high-risk research and development of innovative new therapies.”…

[Click HERE to listen the interview]